Celea Therapeutics

Celea Therapeutics
Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).
About
What does Celea Therapeutics do?
Celea Therapeutics is a clinical-stage biopharmaceutical company focused on developing deupirfenidone, a novel therapeutic candidate for Idiopathic Pulmonary Fibrosis (IPF). The company is a founded entity of PureTech Health plc and aims to establish deupirfenidone as a new standard of care for IPF patients.
What is Celea Therapeutics's revenue?
StartupHub estimates Celea Therapeutics's annual revenue at $8.5M (range $4.6M to $27.5M, 68% confidence), based on comparable companies in the sector.
What is Celea Therapeutics's valuation?
StartupHub estimates Celea Therapeutics's effective valuation at $1.5B (range $900.0M to $2.2B, 23% confidence), based on comparable companies in the sector.
How much funding has Celea Therapeutics raised?
Celea Therapeutics has raised a total of $360M in funding. The most recent round on record is Funding Round.
Where is Celea Therapeutics headquartered?
Celea Therapeutics is headquartered in Boston, Massachusetts, USA.
What industry does Celea Therapeutics operate in?
Celea Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech, Biotech, Drug Discovery, Clinical Trials.
How many employees does Celea Therapeutics have?
Celea Therapeutics has approximately 83 people on record.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
A company focused on privacy, Zcash accumulation, and developing cancer therapeutics.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.